Glucose-6-phosphate dehydrogenase
Glucose-6-phosphate dehydrogenase (G6PD) is a protein enzyme that functions at the entry point of the oxidative pentose phosphate pathway (PPP).
Glucose-6-phosphate dehydrogenase (G6PD) is a protein enzyme that functions at the entry point of the oxidative pentose phosphate pathway (PPP). The publication contexts provided identify G6PD as a major determinant of NADPH production, with downstream effects on glutathione (GSH) regeneration, reactive oxygen species (ROS), oxidative stress, and lipid peroxidation. These functions connect G6PD activity to cellular redox balance, tumor-cell survival, ferroptosis, vascular smooth muscle cell behavior, and macrophage–tumor interactions.
G6PD is also a pharmacologically relevant target. Its inhibition has been investigated in malignancies, including pancreatic and lung cancer, and in oxidative vascular disease. Conversely, reduced G6PD activity or G6PD deficiency is clinically relevant to the hemolytic risk associated with high-dose primaquine and tafenoquine. Recent work further examines allosteric inhibition, endogenous metabolic regulators such as itaconic acid, and transcriptional or post-translational mechanisms that alter G6PD activity.
Where the papers sit
10 papers from the last 6 months study glucose-6-phosphate dehydrogenase directly · updated from PubMed 6 Nov 2026
Study type 0 clinical trials · 2 human data · 6 preclinical · 2 unclassified
Themes 3 themes · 1 new direction
-
Redox Stress across Diseases
G6PD-linked oxidative stress is being examined across vascular inflammation, pancreatic drug retention, and β-cell failure. Inhibition or suppression of G6PD reduces NADPH support and reshapes redox responses, with effects on aneurysm formation, chemotherapy handling, and type 1 diabetes. Allosteric mapping of G6PDi-1 moves the field toward more precise pharmacology. Primaquine and tafenoquine risk perceptions address a related clinical safety question but do not establish a unified therapeutic direction.
5 papers · 50%
-
Metabolic Vulnerabilities in Lung Cancer
Metabolic control of lung cancer is moving toward exploiting G6PD dependence rather than treating the pentose phosphate pathway as background metabolism. Itaconate and IRG1 can inhibit G6PD while rewiring macrophage–tumor metabolism, and related work frames itaconate as a lung-cancer metabolic regulator. In small-cell lung cancer, AKT/NRF2 signaling modifies sensitivity to vitamin C through G6PD. Spatial transcriptomics and adaptation analyses point to tumor context and cell state as unresolved determinants of response.
3 papers · 30%
-
Redox Control of Cancer Resistance
Redox metabolism is being linked to whether cancer cells withstand treatment or undergo ferroptosis. LZTFL1-driven NADPH–glutathione rewiring is presented as a way to amplify ferroptotic death. In pancreatic cancer, mitophagy-competent cancer-associated fibroblasts support chemoresistance by redirecting pyrimidine metabolism, highlighting the stromal compartment as a resistance mechanism. The open question is whether G6PD-centered metabolic intervention can overcome these tumor and microenvironment defenses.
2 papers · 20%
G6PD is an effector of itaconate-driven immune reprogramming in the lung tumor microenvironment
The IRG1/itaconate study in human and mouse lung tumors found that G6PD is not only a tumor-cell metabolic enzyme or pharmacological target, but also a mediator of macrophage–tumor metabolic communication. Endogenous itaconate from tumor-associated macrophages inhibited G6PD and the pentose phosphate pathway in cancer cells and pro-tumor macrophages, suppressing tumor growth while converting macrophages to an anti-tumor state. This assigns G6PD a new role in endogenous immune regulation and macrophage functional reprogramming rather than solely in tumor-intrinsic redox adaptation or growth 42235511Jun.
Papers
The 10 papers from the last 6 months that study glucose-6-phosphate dehydrogenase directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Redox Stress across Diseases (5)
- lncRNA Gm10451 mediates β-cell functional impairment in type 1 diabetes through the miR-24-3p/G6PD axis. Endocrine · 11 Sept 2026 PMID 42726386
- Glycyrrhetinic Acid and Autocrine Motility Factor Converge on G6PD Suppression, Oxidative Stress, and Drug Retention to Impair Pancreatic Ductal Adenocarcinoma Cell Growth. Anticancer research · 29 Jul 2026 PMID 42527054
- G6PD inhibition prevents abdominal aortic aneurysm formation in mice induced by Ang II plus high salt. Atherosclerosis · 15 Jul 2026 PMID 42456310
- Risk perceptions of high-dose primaquine and tafenoquine among Plasmodium vivax malaria stakeholders in Ethiopia: a qualitative study. BMJ global health · 29 Jun 2026 PMID 42373213
- Mapping the Binding Landscape of Allosteric Inhibitor G6PDi-1 on Human G6PD. The journal of physical chemistry letters · 18 Jun 2026 PMID 42311042
Metabolic Vulnerabilities in Lung Cancer (3)
- Modulation of G6PD-mediated Vitamin C Sensitivity in Small Cell Lung Cancer by the AKT/NRF2 axis. The Journal of biological chemistry · 5 Nov 2026 PMID 42988119
- Jack-of-a-new-trade: Itaconate targets the PPP/G6PD to control lung cancer. Cell metabolism · 7 Jul 2026 PMID 42413476
- IRG1/itaconate rewires macrophage and lung tumor metabolism through G6PD inhibition. Cell metabolism · 3 Jun 2026 PMID 42235511
Redox Control of Cancer Resistance (2)
- LZTFL1 rewires NADPH-glutathione metabolism to amplify ferroptosis. Molecular cell · 4 Aug 2026 PMID 42551439
- Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer. Cancer research · 27 May 2026 PMID 42202065
By study type
Human data, design not indexed (2)
- Risk perceptions of high-dose primaquine and tafenoquine among Plasmodium vivax malaria stakeholders in Ethiopia: a qualitative study. BMJ global health · 29 Jun 2026 PMID 42373213
- Mapping the Binding Landscape of Allosteric Inhibitor G6PDi-1 on Human G6PD. The journal of physical chemistry letters · 18 Jun 2026 PMID 42311042
Preclinical: animal, cell and lab studies (6)
- lncRNA Gm10451 mediates β-cell functional impairment in type 1 diabetes through the miR-24-3p/G6PD axis. Endocrine · 11 Sept 2026 PMID 42726386
- LZTFL1 rewires NADPH-glutathione metabolism to amplify ferroptosis. Molecular cell · 4 Aug 2026 PMID 42551439
- Glycyrrhetinic Acid and Autocrine Motility Factor Converge on G6PD Suppression, Oxidative Stress, and Drug Retention to Impair Pancreatic Ductal Adenocarcinoma Cell Growth. Anticancer research · 29 Jul 2026 PMID 42527054
- G6PD inhibition prevents abdominal aortic aneurysm formation in mice induced by Ang II plus high salt. Atherosclerosis · 15 Jul 2026 PMID 42456310
- Jack-of-a-new-trade: Itaconate targets the PPP/G6PD to control lung cancer. Cell metabolism · 7 Jul 2026 PMID 42413476
- Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer. Cancer research · 27 May 2026 PMID 42202065
Unclassified: not yet indexed with MeSH (2)
- Modulation of G6PD-mediated Vitamin C Sensitivity in Small Cell Lung Cancer by the AKT/NRF2 axis. The Journal of biological chemistry · 5 Nov 2026 PMID 42988119
- IRG1/itaconate rewires macrophage and lung tumor metabolism through G6PD inhibition. Cell metabolism · 3 Jun 2026 PMID 42235511
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-09-05. Last written: 2026-09-13 by GPT. Drafted by language models from published abstracts; not medical advice.